De Novo Pharmaceuticals
De Novo Launches ‘Stand-Alone; SkelGen
1st June 2011
For some years, big pharma and large biotechs have accessed the power of De Novo’s in silico drug discovery platform through partnerships with De Novo’s scientists. SkelGen is upgraded to allow independent use by all those involved in medicinal and computational chemistry. A new low-entry barrier ‘pay-per-view’ business model now makes in silico drug discovery available to scientists throughout the pharmaceutical industry.

Print this page



 
Recent News
De Novo Agrees Med Chem Synthesis Deal
De Novo Launches Academic Access Programme
De Novo Takes SkelGen to Japan
De Novo Launches ‘Stand-Alone; SkelGen
De Novo signs first academic licence with the University of Hertfordshire
De Novo Pharmaceuticals announces a Drug Discovery Partnership agreement with Achaogen
De Novo Pharmaceuticals Ltd. Announces New Partnering Opportunity in Diabetes
De Novo Pharmaceuticals Ltd. Announces New Therapeutic Focus In the Area Of Metabolic Diseases And Appoints New Scientific Advisory Board.
De Novo Pharmaceuticals Ltd Announces Drug Discovery Collaboration Agreement with Genzyme
De Novo launches Reflex, a major upgrade to its in silico drug design platform